Estimating the cost-effectiveness of a sequential pneumococcal vaccination program for adults in Germany.

ABSTRACT: INTRODUCTION:In Germany, a 23-valent polysaccharide pneumococcal vaccine (PPSV23) is recommended for elderly (60+) and patients 16+ with chronic diseases not associated with immune suppression. For all other patients at risk, sequential immunization with a 13-valent pneumococcal conjugate vaccine (PCV13) first, followed by PPSV23 is recommended. Repeated vaccination with PPSV23 is recommended every 6 years after individual assessment by the physician. This was adopted into the vaccination directive with binding reimbursement and funding. However, additional voluntary services allow statutory health insurances to differentiate from each other. Aim of this study is to estimate the cost-effectiveness of voluntary service scenarios compared to the strategy in place to support informed decision

SUBMITTER: Kuchenbecker U 

PROVIDER: S-EPMC5967715 | biostudies-literature | 2018

REPOSITORIES: biostudies-literature